📊 AI Stock Rating — Summary

Alnylam Pharmaceuticals reported quarterly revenue of approximately $1.25 billion, generating a net income of $251 million and resulting in earnings per share (EPS) of $1.91. The company's net margin stood at 20.1%, indicating strong profitability. Free cash flow was robust at $313 million, highlighting efficient cash generation. Year-over-year revenue growth rate from comparable periods is a critical factor to consider, though specific growth figures require context from previous results. Alnylam demonstrates solid profitability with a notable EPS of $1.91, supported by efficient operations that yield a significant net margin. While the company does not currently distribute dividends, it maintains a liquidity cushion with substantial cash reserves of over $1.49 billion. A negative net debt position reflects financial resilience, enhancing its ability to withstand market fluctuations. The absence of debt repayments and stock repurchase activity suggests a focus on internal reinvestment and balance sheet strength. Analysts have set price targets ranging up to $570, suggesting potential market appreciation. Alnylam's performance showcases growth potential while effectively managing cash flows and maintaining a solid financial position, which is promising for investors.

AI Score Breakdown

Revenue Growth — Score: 6/10

Revenue stood at approximately $1.25 billion. While specific annual growth rates are absent, the release indicates positive trends. Alnylam's revenue trajectory seems stable, driven by product innovation and expanding market presence.

Profitability — Score: 8/10

Strong profitability is evident with a net margin of 20.1% and EPS of $1.91, suggesting efficient operations. Sustained margin performance highlights effective cost management.

Cash Flow Quality — Score: 7/10

Free cash flow was solid at $313 million, supporting business operations and potential future investments. No dividends or buyback plans currently, maintaining cash for strategic uses.

Leverage & Balance Sheet — Score: 9/10

A negative net debt position enhances financial flexibility. Total equity is low relative to assets, but high cash reserves of $1.49 billion provide a buffer against liabilities.

Shareholder Returns — Score: 5/10

Absent dividends and buybacks, shareholder returns hinge on market performance. Positive price targets suggest investor confidence, yet without dividend or buyback initiatives, tangible returns are neutral.

Analyst Sentiment & Valuation — Score: 8/10

Analyst targets indicate potential upside with a median of $495 against current market valuations. Strong sentiment reflects confidence in Alnylam's strategic direction and growth prospects.

⚠ AI-generated — informational only, not financial advice.